SK287270B6
(sk)
*
|
1998-11-10 |
2010-05-07 |
Janssen Pharmaceutica N. V. |
Derivát pyrimidínu
|
GB9914258D0
(en)
*
|
1999-06-18 |
1999-08-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
NZ517025A
(en)
|
1999-09-24 |
2003-07-25 |
Janssen Pharmaceutica Nv |
Antiviral compositions
|
DE19945982A1
(de)
*
|
1999-09-24 |
2001-03-29 |
Knoll Ag |
Geschwindigkeitsbestimmte Partikel
|
ATE396978T1
(de)
|
1999-10-07 |
2008-06-15 |
Amgen Inc |
Triazin-kinase-hemmer
|
US20030004174A9
(en)
|
2000-02-17 |
2003-01-02 |
Armistead David M. |
Kinase inhibitors
|
AU783981C
(en)
*
|
2000-05-08 |
2007-05-03 |
Janssen Pharmaceutica N.V. |
HIV replication inhibitors
|
CA2407754C
(en)
*
|
2000-05-08 |
2009-09-15 |
Janssen Pharmaceutica N.V. |
Prodrugs of hiv replication inhibiting pyrimidines
|
WO2002056132A2
(en)
*
|
2000-11-01 |
2002-07-18 |
Snapnames Com Inc |
Domain name acquisition and management system and method
|
US6958211B2
(en)
|
2001-08-08 |
2005-10-25 |
Tibotech Bvba |
Methods of assessing HIV integrase inhibitor therapy
|
US8101629B2
(en)
|
2001-08-13 |
2012-01-24 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
|
JO3429B1
(ar)
|
2001-08-13 |
2019-10-20 |
Janssen Pharmaceutica Nv |
مشتقات برميدينات مثبطة فيروس الايدز
|
US7638522B2
(en)
|
2001-08-13 |
2009-12-29 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
WO2003032994A2
(de)
|
2001-10-17 |
2003-04-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
|
ES2314106T3
(es)
|
2001-10-17 |
2009-03-16 |
BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG |
Derivados de pirimidina, agentes farmaceuticos que contiene dichos compuestos, uso y metodo para su obtencion.
|
WO2003037891A1
(en)
|
2001-11-01 |
2003-05-08 |
Janssen Pharmaceutica N.V. |
Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
|
EA007578B1
(ru)
|
2001-11-01 |
2006-12-29 |
Янссен Фармацевтика Н.В. |
Производные амидов в качестве ингибиторов гликогенсинтаза-киназы 3-бета
|
SE0104140D0
(sv)
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
PL213783B1
(pl)
|
2002-03-13 |
2013-05-31 |
Janssen Pharmaceutica Nv |
Podstawiona pochodna piperydyny lub piperazyny, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
|
PL214279B1
(pl)
|
2002-03-13 |
2013-07-31 |
Janssen Pharmaceutica Nv |
Pochodna sulfonyloaminowa, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
EA008244B1
(ru)
*
|
2002-05-03 |
2007-04-27 |
Янссен Фармацевтика Н.В. |
Полимерные микроэмульсии
|
AR039540A1
(es)
|
2002-05-13 |
2005-02-23 |
Tibotec Pharm Ltd |
Compuestos microbicidas con contenido de pirimidina o triazina
|
TW200409629A
(en)
|
2002-06-27 |
2004-06-16 |
Bristol Myers Squibb Co |
2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
|
CN1678321A
(zh)
|
2002-07-29 |
2005-10-05 |
里格尔药品股份有限公司 |
用2,4-嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
|
KR101140785B1
(ko)
|
2002-08-09 |
2012-05-03 |
얀센 파마슈티카 엔.브이. |
4-〔〔4-〔〔4-(2-시아노에테닐)-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법
|
CA2499550C
(en)
*
|
2002-09-20 |
2013-10-15 |
Alpharma, Inc. |
Sequestering subunit and related compositions and methods
|
WO2004048343A1
(en)
*
|
2002-11-28 |
2004-06-10 |
Schering Aktiengesellschaft |
Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
|
EA011009B1
(ru)
|
2003-01-14 |
2008-12-30 |
Арена Фармасьютикалз Инк. |
1,2,3-тризамещённые арильные и гетероарильные производные в качестве модуляторов метаболизма и профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия
|
KR20110132482A
(ko)
|
2003-02-07 |
2011-12-07 |
얀센 파마슈티카 엔.브이. |
Hiv 감염 예방용 피리미딘 유도체
|
BRPI0407306A
(pt)
*
|
2003-02-07 |
2006-02-21 |
Janssen Pharmaceutica Nv |
1,2,4- triazinas de inibição de hiv
|
ES2325440T3
(es)
*
|
2003-02-20 |
2009-09-04 |
Smithkline Beecham Corporation |
Compuestos de pirimidina.
|
CL2004000306A1
(es)
*
|
2003-02-20 |
2005-04-08 |
Tibotec Pharm Ltd |
Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
|
CN1822843B
(zh)
*
|
2003-07-17 |
2010-04-28 |
泰博特克药品有限公司 |
制备含有抗病毒药物颗粒的方法
|
BRPI0413018B8
(pt)
|
2003-07-30 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, e, uso de um composto
|
US8026245B2
(en)
*
|
2003-09-25 |
2011-09-27 |
Janssen Pharmaceutica N.V. |
HIV replication inhibiting purine derivatives
|
CA2557790A1
(en)
|
2004-03-02 |
2005-09-15 |
Virco Bvba |
Estimation of clinical cut-offs
|
EP1598343A1
(de)
|
2004-05-19 |
2005-11-23 |
Boehringer Ingelheim International GmbH |
2-Arylaminopyrimidine als PLK Inhibitoren
|
AU2005266312C1
(en)
|
2004-07-28 |
2011-06-16 |
Janssen Pharmaceutica N.V. |
Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
|
US7923554B2
(en)
|
2004-08-10 |
2011-04-12 |
Janssen Pharmaceutica N.V. |
HIV inhibiting 1,2,4-triazin-6-one derivatives
|
JP5046943B2
(ja)
*
|
2004-09-30 |
2012-10-10 |
テイボテク・フアーマシユーチカルズ |
Hiv阻害性5−置換ピリミジン
|
RU2403244C2
(ru)
|
2004-09-30 |
2010-11-10 |
Тиботек Фармасьютикалз Лтд. |
Вич-ингибирующие 5-карбо- или гетероциклические замещенные пиримидины
|
AU2005288864B2
(en)
|
2004-09-30 |
2012-08-23 |
Janssen Sciences Ireland Uc |
HIV inhibiting 5-heterocyclyl pyrimidines
|
RU2403254C2
(ru)
|
2004-10-29 |
2010-11-10 |
Тиботек Фармасьютикалз Лтд. |
Бициклические производные пиримидина, ингибирующие вич
|
US20060106043A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Boehringer Ingelheim International Gmbh |
Method for treating HIV infection through co-administration of tipranavir and etravirine
|
WO2006068770A1
(en)
|
2004-11-24 |
2006-06-29 |
Rigel Pharmaceuticals, Inc. |
Spiro-2, 4-pyrimidinediamine compounds and their uses
|
EP2161275A1
(en)
|
2005-01-19 |
2010-03-10 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
BRPI0607214B8
(pt)
*
|
2005-01-27 |
2021-05-25 |
Janssen R & D Ireland |
derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação
|
DK1853588T3
(da)
|
2005-02-16 |
2008-09-15 |
Astrazeneca Ab |
Kemiske forbindelser
|
EP1853567B1
(en)
|
2005-02-18 |
2014-12-31 |
Janssen R&D Ireland |
Hiv inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
|
JP5118978B2
(ja)
*
|
2005-03-04 |
2013-01-16 |
テイボテク・フアーマシユーチカルズ |
Hiv阻害2−(4−シアノフェニル)−6−ヒドロキシルアミノピリミジン
|
MX2007014328A
(es)
|
2005-05-16 |
2008-02-12 |
Astrazeneca Ab |
Compuestos quimicos.
|
EP1888537B1
(en)
*
|
2005-05-26 |
2013-09-11 |
Janssen R&D Ireland |
Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino benzonitrile
|
KR101312225B1
(ko)
|
2005-06-08 |
2013-09-26 |
리겔 파마슈티칼스, 인크. |
Jak 경로의 억제를 위한 조성물 및 방법
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
EP1945208A4
(en)
*
|
2005-10-06 |
2011-08-03 |
Univ Massachusetts |
COMPOSITION AND SYNTHESIS OF NEW REAGENTS TO INHIBIT HIV REPLICATION
|
NZ567584A
(en)
|
2005-10-28 |
2011-08-26 |
Astrazeneca Ab |
4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
|
WO2007082882A1
(en)
|
2006-01-19 |
2007-07-26 |
Janssen Pharmaceutica N.V. |
Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
|
CA2630717C
(en)
|
2006-01-19 |
2015-02-24 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
ATE432272T1
(de)
|
2006-01-19 |
2009-06-15 |
Janssen Pharmaceutica Nv |
Aminophenylderivate als neue inhibitoren von histondeacetylase
|
EP1991532B1
(en)
|
2006-02-24 |
2017-01-11 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
JP5078986B2
(ja)
|
2006-03-30 |
2012-11-21 |
テイボテク・フアーマシユーチカルズ |
Hivを阻害する5−アミド置換されたピリミジン
|
JP5070278B2
(ja)
|
2006-03-30 |
2012-11-07 |
テイボテク・フアーマシユーチカルズ |
Hivを阻害する5−(ヒドロキシメチレンおよびアミノメチレン)置換されたピリミジン
|
PE20080068A1
(es)
|
2006-05-15 |
2008-03-17 |
Boehringer Ingelheim Int |
Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
|
EP2029110B1
(en)
*
|
2006-06-06 |
2011-08-31 |
Tibotec Pharmaceuticals |
Process for preparing spray dried formulations of tmc125
|
PT2484346T
(pt)
|
2006-06-19 |
2017-04-26 |
Alpharma Pharmaceuticals Llc |
Composições farmacêuticas
|
US20080233156A1
(en)
*
|
2006-10-11 |
2008-09-25 |
Alpharma, Inc. |
Pharmaceutical compositions
|
US20100041687A1
(en)
*
|
2006-12-06 |
2010-02-18 |
Thone Daniel Joseph Christiaan |
Hydrobromide salt of an anti-hiv compound
|
US9006243B2
(en)
|
2006-12-29 |
2015-04-14 |
Janssen R&D Ireland |
HIV inhibiting 6-substituted pyrimidines
|
AU2007341228B2
(en)
|
2006-12-29 |
2013-04-18 |
Janssen Sciences Ireland Uc |
HIV inhibiting 5,6-substituted pyrimidines
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
US8410124B2
(en)
|
2007-10-18 |
2013-04-02 |
Concert Pharmaceuticals Inc. |
Deuterated etravirine
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
WO2009079521A1
(en)
*
|
2007-12-17 |
2009-06-25 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
NO2300013T3
(ko)
|
2008-05-21 |
2018-02-03 |
|
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
MX360970B
(es)
|
2008-06-27 |
2018-11-23 |
Avila Therapeutics Inc |
Compuestos de heteroarilo y usos de los mismos.
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
AR073760A1
(es)
*
|
2008-10-03 |
2010-12-01 |
Astrazeneca Ab |
Derivados heterociclicos y metodos de uso de los mismos
|
US20110071158A1
(en)
*
|
2009-03-18 |
2011-03-24 |
Boehringer Ingelheim International Gmbh |
New compounds
|
AU2010230344B9
(en)
|
2009-03-30 |
2014-11-27 |
Janssen Sciences Ireland Uc |
Co-crystal of etravirine and nicotinamide
|
JP5918693B2
(ja)
|
2009-05-05 |
2016-05-18 |
ダナ ファーバー キャンサー インスティテュート インコーポレイテッド |
Egfr阻害剤及び疾患の治療方法
|
WO2010131118A2
(en)
*
|
2009-05-12 |
2010-11-18 |
Pliva Hrvatska D.O.O. |
Polymorphs of etravirine and processes for preparation thereof
|
WO2010150279A2
(en)
|
2009-06-22 |
2010-12-29 |
Emcure Pharmaceuticals Limited |
Process for synthesis of diarylpyrimidine non-nucleoside reverse transcriptase inhibitor
|
WO2011017079A1
(en)
|
2009-07-27 |
2011-02-10 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation and purification of etravirine and intermediates thereof
|
GR1007010B
(el)
|
2009-10-08 |
2010-10-07 |
Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), |
Ινσουλινοειδη πεπτιδια
|
PT2576541T
(pt)
|
2010-06-04 |
2016-07-08 |
Hoffmann La Roche |
Derivados de aminopirimidina como moduladores de lrrk2
|
US8598341B2
(en)
|
2010-06-28 |
2013-12-03 |
Hetero Research Foundation |
Process for etravirine intermediate and polymorphs of etravirine
|
CN103096716B
(zh)
|
2010-08-10 |
2016-03-02 |
西建阿维拉米斯研究公司 |
Btk抑制剂的苯磺酸盐
|
WO2012040279A1
(en)
|
2010-09-22 |
2012-03-29 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
NZ609957A
(en)
|
2010-11-01 |
2015-08-28 |
Celgene Avilomics Res Inc |
Heterocyclic compounds and uses thereof
|
US9238629B2
(en)
|
2010-11-01 |
2016-01-19 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
JP5957003B2
(ja)
|
2010-11-10 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
変異体選択的egfr阻害剤およびその使用
|
PT2638031T
(pt)
|
2010-11-10 |
2018-01-03 |
Genentech Inc |
Derivados de pirazol aminopirimidina como moduladores de lrrk2
|
PL2702045T3
(pl)
|
2011-04-26 |
2018-04-30 |
Mylan Laboratories Ltd. |
Nowy sposób sporządzania Etrawiryny
|
EA201391626A1
(ru)
|
2011-05-04 |
2014-03-31 |
Ариад Фармасьютикалз, Инк. |
Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
|
WO2012170647A1
(en)
*
|
2011-06-09 |
2012-12-13 |
Assia Chemical Industriew Ltd. |
Process for the preparation of etravirine and intermediates in the synthesis thereof
|
JP5993010B2
(ja)
|
2011-08-23 |
2016-09-14 |
エンドゥ ファーマシューティカルズ,インコーポレイティド |
ピリミド−ピリダジノン化合物及びその使用
|
WO2013059572A1
(en)
|
2011-10-19 |
2013-04-25 |
Assia Chemical Industries Ltd. |
Process for the preparation of etravirine and intermediates in the synthesis thereof
|
US9364476B2
(en)
|
2011-10-28 |
2016-06-14 |
Celgene Avilomics Research, Inc. |
Methods of treating a Bruton's Tyrosine Kinase disease or disorder
|
US8703786B2
(en)
*
|
2011-12-07 |
2014-04-22 |
Texas Southern University |
Etravirine formulations and uses thereof
|
CN108658873B
(zh)
|
2012-03-15 |
2021-09-14 |
西建卡尔有限责任公司 |
表皮生长因子受体激酶抑制剂的固体形式
|
US9108927B2
(en)
|
2012-03-15 |
2015-08-18 |
Celgene Avilomics Research, Inc. |
Salts of an epidermal growth factor receptor kinase inhibitor
|
JP6469567B2
(ja)
|
2012-05-05 |
2019-02-13 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Egfr発動性がんの細胞増殖阻害用化合物
|
US20150336900A1
(en)
*
|
2012-10-29 |
2015-11-26 |
Biophore India Pharmaceuticals Pvt. Ltd. |
Process for the Synthesis of Etravirine and Its Intermediates
|
WO2014072419A1
(en)
|
2012-11-08 |
2014-05-15 |
Universiteit Antwerpen |
Novel anti-hiv compounds
|
JP6370801B2
(ja)
|
2012-12-21 |
2018-08-08 |
ベルリクス・ファーマ・インコーポレイテッド |
肝疾患または肝障害の治療のための使用および方法
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
MX2015009952A
(es)
|
2013-02-08 |
2015-10-05 |
Celgene Avilomics Res Inc |
Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
DK3179858T3
(da)
|
2014-08-13 |
2019-07-22 |
Celgene Car Llc |
Forme og sammensætninger af en ERK-inhibitor
|
MX2021011472A
(es)
|
2015-01-06 |
2022-08-17 |
Arena Pharm Inc |
Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
|
CN104926829A
(zh)
*
|
2015-06-08 |
2015-09-23 |
山东大学 |
一种噻吩并嘧啶类衍生物及其制备方法和应用
|
US10301262B2
(en)
|
2015-06-22 |
2019-05-28 |
Arena Pharmaceuticals, Inc. |
Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
|
CN110066273A
(zh)
*
|
2019-06-05 |
2019-07-30 |
山东大学 |
一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
|
CA3145864A1
(en)
|
2019-07-03 |
2021-01-07 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
CN111217833B
(zh)
*
|
2020-02-21 |
2021-03-16 |
山东大学 |
噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
|
CN111875548A
(zh)
*
|
2020-07-16 |
2020-11-03 |
山东大学 |
一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用
|